Assentia has unveiled two new proprietary, SaaS-based applications, GrantPay™ and GrantPact™, designed to aid Assentia in merging its global knowledge in clinical trial contract negotiations and investigative site payments with functional technology platforms.
Assentia utilizes GrantPay™ to provide investigator site payments on a multi-currency, global scale in addition to granular forecasting and customizable reporting to assist its clients' needs and obligations.
GrantPact™ is Assentia's proprietary platform supporting its international team in negotiating and tracking global clinical trial agreements, including housing previously negotiated legal clauses with study sites worldwide.
Assentia Unveils Proprietary Software, GrantPay™ and GrantPact™, to Aid in Accelerating Clinical Trial Study-Startup and Investigator Payments. (2023, March 9). Cision PR Newswire.
Unlock Commercial Growth through Data-Driven Patient and HCP Insights
May 2nd 2025Leveraging data-driven patient and healthcare provider (HCP) insights, including social drivers of health (SDOH), is essential for life sciences companies to continuously improve patient engagement and commercial success. Mark Rodgers, AVP of Commercial Analytics at Inovalon, discusses how identifying treatment milestones, assessing HCP performance, and segmenting patient populations using SDOH data can drive targeted strategies that improve healthcare outcomes and market access
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
FDA Approves Nipocalimab for the Treatment of Generalized Myasthenia Gravis
April 30th 2025Approval is based on results from the pivotal Vivacity-MG3 trial in which IMAAVY (nipocalimab-aahu) demonstrated superior disease control throughout 24 weeks when compared to placebo plus standard of care.